Skip to main content
. Author manuscript; available in PMC: 2021 Feb 27.
Published in final edited form as: Immunohorizons. 2021 Jan 15;5(1):16–24. doi: 10.4049/immunohorizons.2000114

Fig 3: Compromised gut mucosal immunity and dysbiosis in uremia.

Fig 3:

At day 10 post AAI injection, SILP (n=5–19) were evaluated for the frequency of (A) macrophages (liveCD45+CD11b+ F4/80+CX3CR1+CD11c+; liveCD45+CD11b+F4/80+CX3CR1+CD11c-), (B) dendritic cells (liveCD45+CD11b+CD103+CD11c+, liveCD45+CD11b-CD103+CD11c+; liveCD45+CD11b+ CD103-CD11c+) (C) neutrophils (liveCD45+CD11b+Ly6G+), (D) Th17 (liveCD45+CD4+IL-17+) and Th1 (liveCD45+CD4+IFNγ+), and (E) IgA producing plasmablasts (liveCD45+CD11b+IgA+; liveCD45+CD11b-IgA+) cells, (F) T regulatory cells (liveCD4+Foxp3+) by FACS at day 10 post AAI injection. (G) Percentages of Th17 and Th1 cells in the MLN (n=8–12) were determined by intra-cellular cytokine staining following in vitro stimulation with PMA/Ionomycin. (H) Frequency of T regulatory cells was determined in the MLN by FACS. (I) At day 10 post AAI injection, fecal pellets from uremic and control (n=5) mice were subjected to targeted 16S rRNA sequencing. Data pooled from at least 2 independent experiments for A-H and expressed as mean ± S.D (A-H). Statistical analyses by One-way ANOVA (A-H) and pairwise using Wilcoxon Rank Sum Test (I).